Progesterone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00396 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 60 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | amenorrhea (disease) | KG + DL |
| 2 | breast fibrocystic disease | KG + DL |
| 3 | benign mammary dysplasia | KG + DL |
| 4 | renal hypoplasia, bilateral | KG + DL |
| 5 | cervix endometriosis | KG + DL |
| 6 | renal hypoplasia (disease) | KG + DL |
| 7 | endometriosis of rectovaginal septum and vagina | KG + DL |
| 8 | endometriosis in cutaneous scar | KG + DL |
| 9 | blunt duct adenosis of breast | KG + DL |
| 10 | apocrine adenosis of breast | KG + DL |
| 11 | gelatinous drop-like corneal dystrophy | KG + DL |
| 12 | infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly | KG + DL |
| 13 | fat necrosis of breast | KG + DL |
| 14 | breast abscess | KG + DL |
| 15 | lactation disease | KG + DL |
| 16 | ovarian endometriosis | KG + DL |
| 17 | caudal duplication | KG + DL |
| 18 | placenta cancer | KG + DL |
| 19 | hyperplastic polyposis syndrome | KG + DL |
| 20 | uterine corpus adenocarcinofibroma | KG + DL |
| 21 | uterine corpus adenosarcoma | KG + DL |
| 22 | sessile serrated polyposis cancer syndrome | KG + DL |
| 23 | uterine corpus choriocarcinoma | KG + DL |
| 24 | uterine carcinosarcoma | KG + DL |
| 25 | uterine corpus endometrial carcinoma | KG + DL |
| 26 | colorectal cancer, hereditary nonpolyposis, | KG + DL |
| 27 | endometrial transitional cell carcinoma | KG + DL |
| 28 | rare variants of adenocarcinoma of the corpus uteri | KG + DL |
| 29 | megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome | KG + DL |
| 30 | uterine corpus carcinofibroma | KG + DL |
| 31 | primitive neuroectodermal tumor of the corpus uteri | KG + DL |
| 32 | Muir-Torre syndrome | KG + DL |
| 33 | uterine corpus mixed epithelial and mesenchymal neoplasm | KG + DL |
| 34 | endometrioid stromal sarcoma | KG + DL |
| 35 | high-grade neuroendocrine carcinoma of the corpus uteri | KG + DL |
| 36 | congenital stromal corneal dystrophy | KG + DL |
| 37 | papillary carcinoma of the corpus uteri | KG + DL |
| 38 | adenoid cystic carcinoma of the corpus uteri | KG + DL |
| 39 | malignant germ cell tumor of corpus uteri | KG + DL |
| 40 | transitional cell carcinoma of the corpus uteri | KG + DL |
| 41 | low-grade neuroendocrine tumor of the corpus uteri | KG + DL |
| 42 | endometrium carcinoma in situ | KG + DL |
| 43 | tamoxifen-related endometrial lesion | KG + DL |
| 44 | endometrial polyp | KG + DL |
| 45 | prostate cancer/brain cancer susceptibility | KG + DL |
| 46 | fibroma of prostate | KG + DL |
| 47 | Brenner tumor | KG + DL |
| 48 | benign reproductive system neoplasm | KG + DL |
| 49 | prostate leiomyoma | KG + DL |
| 50 | hypopigmentation-punctate palmoplantar keratoderma syndrome | KG + DL |
(Showing top 50 of 60 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.